ValueAct Capital, LLC

SAN FRANCISCO, Nov. 1 /PRNewswire/ -- ValueAct Capital today confirmed that it is not implicated in the SEC's insider trading complaint against seven defendants, including its former CFO. George F. Hamel, Jr., ValueAct Capital's Co-Founder and Chief Operating Officer said, "ValueAct Capital remains committed to a culture of strong internal regulatory education and compliance and is a firm believer in the integrity of ...

http://xml.10kwizard.com/filing_raw.php?repo=tenk&ipage=6507796

SAN FRANCISCO, CALIFORNIA -- (MARKET WIRE) -- 09/03/09 -- ValueAct Capital Master Fund, L.P. announced today that it has entered into an agreement with a subsidiary of Danaher Corporation pursuant to which it has agreed to vote its common shares in MDS Inc., in favour of the purchase of MDS Analytical Technologies business by Danaher, as more fully described in the attached Early Warning Report. EARLY WARNING REPORT UNDER NATIONAL INSTRUMENT 62-103 1. Name and Address of Offeror: ValueAct Capital Master Fund, L.P. 435 Pacific Avenue, 4th Floor San Francisco, CA 94133 2. The designation and number or principal amount of securities and the offeror's securityholding percentage in the class of securities of which the offeror acquired ownership ...

SAN FRANCISCO, CALIFORNIA--(Marketwire - Sept. 3, 2009) - ValueAct Capital Master Fund, L.P. announced today that it has entered into an agreement with a subsidiary of Danaher Corporation pursuant to which it has agreed to vote its common shares in MDS Inc., in favour of the purchase of MDS Analytical Technologies business by Danaher, as more fully described in the attached Early Warning Report. EARLY WARNING REPORT UNDER NATIONAL INSTRUMENT 62-103 1. Name and Address of Offeror: ValueAct Capital Master Fund, L.P. 435 Pacific Avenue, 4th Floor San Francisco, CA 94133 2. The designation and number or principal amount of securities and the offeror's securityholding percentage in the class of securities of which the offeror acquired ownership or control ...

In a 13D filing on Immucor Inc. (Nasdaq: BLUD) this morning, San Francisco-based value investors ValueAct Capital disclosed a 5.3%, or 3,715,200 share, stake in the company. The firm did not show a stake in ...